Capalbo and colleagues showed that a high expression of Gal-3 in biopsies of PD-L1+ NSCLC tumours prior to treatment with anti-PD1 successfully distinguished the non-responders from the responders (151). The gene discussed is LGALS3; the disease is non-small cell lung carcinoma.